"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 7 | 2 | 9 |
| 2003 | 13 | 5 | 18 |
| 2004 | 7 | 5 | 12 |
| 2005 | 2 | 7 | 9 |
| 2006 | 4 | 5 | 9 |
| 2007 | 13 | 1 | 14 |
| 2008 | 10 | 5 | 15 |
| 2009 | 7 | 5 | 12 |
| 2010 | 12 | 10 | 22 |
| 2011 | 16 | 2 | 18 |
| 2012 | 15 | 4 | 19 |
| 2013 | 9 | 9 | 18 |
| 2014 | 7 | 4 | 11 |
| 2015 | 3 | 5 | 8 |
| 2016 | 11 | 7 | 18 |
| 2017 | 7 | 3 | 10 |
| 2018 | 13 | 6 | 19 |
| 2019 | 6 | 4 | 10 |
| 2020 | 4 | 7 | 11 |
| 2021 | 8 | 12 | 20 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 4 | 6 |
| 2025 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):784-793.
-
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
-
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 Apr; 202:108417.
-
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025 Jun; 39(6):1152-1162.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk. JAMA Netw Open. 2024 11 04; 7(11):e2446336.
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024 Oct 21; 83(11):1561-1571.
-
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. Mol Oncol. 2025 Jan; 19(1):225-247.
-
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity. Nat Commun. 2024 Jun 28; 15(1):5487.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 01; 30(1):265-270.